Pharmaco-miR: linking microRNAs and drug effects
暂无分享,去创建一个
Noam Shomron | Jeppe Vinther | Jakob Lewin Rukov | Roni Wilentzik | Ishai Jaffe | N. Shomron | Roni Wilentzik | J. L. Rukov | Jeppe Vinther | Ishai Jaffe
[1] Tongbin Li,et al. miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..
[2] Christoph Dieterich,et al. doRiNA: a database of RNA interactions in post-transcriptional regulation , 2011, Nucleic Acids Res..
[3] Y. Takeda,et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells , 2010, British Journal of Cancer.
[4] H E Rockette,et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Chi-Ying F. Huang,et al. miRTarBase: a database curates experimentally validated microRNA–target interactions , 2010, Nucleic Acids Res..
[6] Meng Li,et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways , 2011, Oncogene.
[7] Thomas D. Schmittgen,et al. Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma , 2009, Pancreas.
[8] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[9] Wei De,et al. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549) , 2011, Journal of experimental & clinical cancer research : CR.
[10] Mohsen Khorshid,et al. CLIPZ: a database and analysis environment for experimentally determined binding sites of RNA-binding proteins , 2010, Nucleic Acids Res..
[11] Wen-Tsung Huang,et al. MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. , 2012, International journal of molecular medicine.
[12] W. Filipowicz,et al. Post-transcriptional gene silencing by siRNAs and miRNAs. , 2005, Current opinion in structural biology.
[13] Barbara C Vanderhyden,et al. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. , 2007, Gynecologic oncology.
[14] Gabriel Wong,et al. Stem Cell Marker (Nanog) and Stat-3 Signaling Promote MicroRNA-21 Expression and Chemoresistance in Hyaluronan/CD44-activated Head and Neck Squamous Cell Carcinoma Cells , 2011, Oncogene.
[15] D. Pollock,et al. National surveillance of emergency department visits for outpatient adverse drug events. , 2006, JAMA.
[16] Wilko Weichert,et al. Systematic evaluation of the miRNA‐ome and its downstream effects on mRNA expression identifies gastric cancer progression , 2010, The Journal of pathology.
[17] Hui Zhou,et al. starBase: a database for exploring microRNA–mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data , 2010, Nucleic Acids Res..
[18] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[19] Michael Kertesz,et al. The role of site accessibility in microRNA target recognition , 2007, Nature Genetics.
[20] Shingo Takagi,et al. MicroRNA regulates human vitamin D receptor , 2009, International journal of cancer.
[21] Andrey Golubov,et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin , 2010, International journal of cancer.
[22] Doron Betel,et al. The microRNA.org resource: targets and expression , 2007, Nucleic Acids Res..
[23] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[24] S. Griffiths-Jones,et al. miRBase: microRNA Sequences and Annotation , 2010, Current protocols in bioinformatics.
[25] Joshua M. Stuart,et al. Integrating genotype and phenotype information: an overview of the PharmGKB project , 2001, The Pharmacogenomics Journal.
[26] R. Russell,et al. Animal MicroRNAs Confer Robustness to Gene Expression and Have a Significant Impact on 3′UTR Evolution , 2005, Cell.
[27] David I. Watson,et al. Mir-148a Improves Response to Chemotherapy in Sensitive and Resistant Oesophageal Adenocarcinoma and Squamous Cell Carcinoma Cells , 2011, Journal of Gastrointestinal Surgery.
[28] R. Shiekhattar,et al. Human RISC Couples MicroRNA Biogenesis and Posttranscriptional Gene Silencing , 2005, Cell.
[29] P. Provost,et al. MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases , 2010, Brain Research.
[30] T Chaplin,et al. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis , 2007, Leukemia.
[31] Chun-Yang Fan,et al. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel‐induced multidrug resistance , 2011, Head & neck.
[32] S. Kauppinen,et al. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.
[33] Liu Hong,et al. miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells , 2008, International journal of cancer.
[34] William C Reinhold,et al. MicroRNAs modulate the chemosensitivity of tumor cells , 2008, Molecular Cancer Therapeutics.
[35] Noam Shomron,et al. MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. , 2011, Trends in molecular medicine.
[36] C. Burge,et al. Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.
[37] Noam Shomron,et al. MicroRNAs and pharmacogenomics. , 2010, Pharmacogenomics.
[38] D. Amadori,et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2) , 2010, Proceedings of the National Academy of Sciences.
[39] Anjali J. Koppal,et al. Supplementary data: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites , 2010 .
[40] F. Slack,et al. Small non-coding RNAs in animal development , 2008, Nature Reviews Molecular Cell Biology.
[41] Ali Nahvi,et al. A Parsimonious Model for Gene Regulation by miRNAs , 2011, Science.
[42] Xia Shan,et al. miR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines , 2010, International journal of cancer.
[43] Yuzhuo Pan,et al. MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material. , 2009, Drug Metabolism and Disposition.
[44] D. Banerjee,et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance , 2007, Proceedings of the National Academy of Sciences.
[45] Chunxiang Zhang,et al. MicroRNA-21 in Cardiovascular Disease , 2010, Journal of cardiovascular translational research.
[46] Sharon Marsh,et al. Thymidylate synthase pharmacogenetics , 2005, Investigational New Drugs.
[47] Qin-Hui Tuo,et al. CHANGES IN microRNA (miR) PROFILE AND EFFECTS OF miR‐320 IN INSULIN‐RESISTANT 3T3‐L1 ADIPOCYTES , 2009, Clinical and experimental pharmacology & physiology.
[48] Zun-Ling Li,et al. Regulating A549 cells growth by ASO inhibiting miRNA expression , 2010, Molecular and Cellular Biochemistry.
[49] Zhiwei Wang,et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. , 2010, Cancer research.
[50] C. Burge,et al. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.
[51] Noam Shomron,et al. Pharmacogenomics genes show varying perceptibility to microRNA regulation , 2011, Pharmacogenetics and genomics.
[52] Ugo Boggi,et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. , 2010, Cancer research.
[53] Shingo Takagi,et al. Human CYP24 Catalyzing the Inactivation of Calcitriol Is Post-Transcriptionally Regulated by miR-125b , 2009, Molecular Pharmacology.